News
InteRNA Appoints Andrea van Elsas, Ph.D. to Scientific Advisory Board
March 25, 2019
--Co-inventor of original CTLA4-antibody and immuno-oncology innovator to expand the Company's clinical development expertise--...
Read more
Modra Pharmaceuticals announces first patients treated in phase IIa metastatic breast cancer trial
March 21, 2019
Drug Name : docetaxel + ritonavir
Read more
ISA Pharmaceuticals' Chief Scientific Officer Prof. Dr. Cornelis Melief Receives AACR-CRI Lloyd J. Old Award in Cancer Immunology 2019
March 19, 2019
- Recognition for outstanding and innovative cancer research
Read more
Sapreme Technologies in a 6.8 M€ EU Alliance to Develop an Oligonucleotide Delivery Platform Based on Its Proprietary Endosomal Escape Enhancers
February 20, 2019
Sapreme Technologies has been awarded a 6.8 M€ grant by the European Union.
Read more
Modra Pharmaceuticals Expands Management Team and Provides Corporate Update
December 19, 2018
-- Colin Freund has joined as CEO
-- Dr. Edwin De Wit appointed Head of Oncology Development
-- Dr. Alan Barge appointed Chai...
Read more
ISA Pharmaceuticals' Chief Scientific Officer Prof. Cornelis Melief Receives ESMO Immuno-Oncology Award 2018
November 13, 2018
Leiden, The Netherlands, November 13, 2018 - ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology company, today announce...
Read more
Dr. Axel Mescheder appointed CEO of Cristal Therapeutics as focus intensifies on proprietary oncology nanomedicine pipeline
November 02, 2018
Maastricht, The Netherlands, 2nd November 2018 -
Cristal Therapeutics, a clinical stage pharmaceutical company developing targ...
Read more
Cristal Therapeutics Initiates Phase 2 Clinical Trial of Innovative CriPec® Nanomedicine Drug Candidate in Ovarian Cancer
October 24, 2018
Maastricht, The Netherlands, 25th October 2018 - Cristal Therapeutics, a clinical stage pharmaceutical company developing uniqu...
Read more
InteRNA Presents Expanded Preclinical Proof-of-concept Data on Lead Oncology Development Candidate INT-1B3 at the 14th Annual OTS Meeting
October 01, 2018
--Two poster presentations highlight INT-1B3's immune-system activation and CD8+ T cell-driven anti-tumor response in addition...
Read more
Macrophage Pharma Announces Appointment of Leading International Scientific Advisory Board
September 10, 2018
10th September 2018, Windsor, UK: Macrophage Pharma Limited ('MPL'), a company focused on the discovery and development of next...
Read more
Inthera Bioscience AG expands management team with seasoned professionals and secures €4.7 million second tranche of €9.6 million Series A financing
June 26, 2018
Wädenswil, Switzerland, June 6th, 2018
Inthera Bioscience AG, a pre-clinical stage oncology company targeting the inhibition...
Read more
InteRNA Demonstrates Preclinical Proof-of-Concept for Lead microRNA Candidate INT-1B3 in a Range of Cancer Models at 2018 AACR Annual Meeting
April 18, 2018
--INT-1B3 targets multiple hallmarks of cancer as a single agent resulting in immune-system activation, tumor regression and pr...
Read more
Macrophage Pharma Appoints Dr Michael Moore as Chairman
April 11, 2018
11 April 2018, Windsor, UK: Macrophage Pharma Limited ('MPL'), a company focused on the discovery and development of next-gener...
Read more
MIMETAS Secures 20 Million Dollar Series B Financing
April 11, 2018
Global leader in organ-on-a-chip technology backed by international syndicate for worldwide commercial expansion and new produc...
Read more
ISA Pharmaceuticals and Regeneron Announce Strategic Immuno-Oncology Collaboration
December 19, 2017
Leiden, The Netherlands, December 18, 2017, - ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company, and Regeneron P...
Read more
Cristal Therapeutics awarded €2.5 million Horizon 2020 grant to advance its CriPec®-docetaxel through Phase 2 trials
November 28, 2017
Maastricht, The Netherlands, 28 November 2017 - Cristal Therapeutics, a clinical stage biopharmaceutical company developing tar...
Read more
Macrophage Pharma Limited Presents Data on Lead Immuno-Oncology Programme at 32nd Annual Society for Immunotherapy of Cancer (SITC) Conference
November 07, 2017
7 November 2017, Windsor, UK: Macrophage Pharma Limited ('MPL') the immuno-oncology research and development company focused on...
Read more
Cristal Therapeutics progresses nanomedicine CriPec®-docetaxel to phase 1b development in patients with solid tumours
November 01, 2017
Maastricht, The Netherlands, 1 November 2017 - Cristal Therapeutics, a clinical stage biopharmaceutical company developing targ...
Read more
Prof. Dr. Cornelis Melief Receives Honorary Doctorate from Johannes Gutenberg University Mainz
October 26, 2017
- Ceremony Conventio Medicinae held at University Medical Center
Leiden, The Netherlands, October 26, 2017 - ISA Pharmaceuti...
Read more
Phase I results with ModraDoc006/r published in the European Journal of Cancer
October 15, 2017
14 october 2017
Researchers from the Netherlands Cancer Institute have published results from a Phase I study with oral do...
Read more
